Daré Bioscience, Inc. (DARE)
Nasdaq · Healthcare · Biotechnology
$0.8431+0.04%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $16.6M
- 52-week range
- $0.69 – $3.78
- 52-week change
- −62.53%
- EPS (trailing)
- −$0.71
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $1.0M (+10429.44%)
- Net income
- −$13.4M
- Operating margin
- −1315.5%
- Diluted EPS
- −$1.20
- Free cash flow
- −$10.3M
From the company’s annual report on SEC EDGAR.
About Daré Bioscience, Inc.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies.
Headquarters: San Diego, United States · 21 employees · darebioscience.com